This non-randomized phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab or Tislelizumab combined with Lenvatinib as neoadjuvant treatment for resectable RHCC patients
Diagnosed as recurrent hepatocellular carcinoma after curative treatment;
The criteria for resectability is met;
Has at least one evaluable lesion according to the RECIST 1.1 standard and has not received local treatment;
Eastern Cooperative Oncology Group score 0-1, Child-pugh score 5-7;
Previously received any transarterial chemoembolization and immune therapy and other local or systemic liver cancer treatments, except for curative ablation;
Extrahepatic metastasis;
History of gastroesophageal varices or active cardia ulcers associated with a high risk of bleeding;
History of autoimmune disease or need to take immunosuppressant drugs for a long time;